Literature DB >> 2840574

Immunoglobulin and T cell receptor beta chain gene DNA probes in the diagnosis and classification of human lymphoid neoplasia.

D M Knowles1, P G Pelicci, R Dalla-Favera.   

Abstract

The application of DNA probes to demonstrate clonal rearrangements of the immunoglobulin heavy and light chain and T cell receptor beta chain gene loci by Southern blot hybridization analysis has led to significant advances in our ability to diagnose, classify and investigate the lymphoproliferative disorders. This approach has allowed us to conclusively determine the B or T cell lineage derivation and the clonal nature of the vast majority of lymphoid neoplasms, resulting in a new level of understanding of the biology of lymphoid neoplasia. Further application of these DNA probes to other poorly defined and controversial lymphoproliferative disorders should clarify their nature as well. Eventually, antigen receptor gene rearrangement analysis may become routinely employed in diagnosing lymphoid malignancies, monitoring the effects of chemotherapy, detecting early subclinical relapses and identifying disease progression, especially with respect to detecting the emergence of new clonal populations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2840574     DOI: 10.1016/0890-8508(87)90004-1

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN: 0890-8508            Impact factor:   2.365


  3 in total

1.  Dual genotype in cutaneous T-cell lymphomas and pseudolymphomas.

Authors:  Y J Bignon; P Souteyrand; H Roger; D Bernard; B Dastugue; F Ramos; M d'Incan; P Chollet; R Plagne
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

Review 2.  Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia.

Authors:  D M Knowles
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

3.  Peripheral blood involvement in non-Hodgkin's lymphoma detected by clonal gene rearrangement as a biological prognostic marker.

Authors:  L R Hiorns; J Nicholls; J P Sloane; A Horwich; S Ashley; M Brada
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.